Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy

被引：0
作者：
Rossella Parini
Paola De Lorenzo
Andrea Dardis
Alberto Burlina
Alessandra Cassio
Paolo Cavarzere
Daniela Concolino
Roberto Della Casa
Federica Deodato
Maria Alice Donati
Agata Fiumara
Serena Gasperini
Francesca Menni
Veronica Pagliardini
Michele Sacchini
Marco Spada
Roberta Taurisano
Maria Grazia Valsecchi
Maja Di Rocco
Bruno Bembi
机构：
[1] Pediatric Rare Diseases Unit,Centre of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery
[2] Department of Pediatrics,Centre for Rare Diseases
[3] MBBM Foundation,Department for Women and Children’s Health, U.O.C. Inborn Metabolic Diseases
[4] ATS Monza e Brianza,Department of Pediatrics
[5] University of Milano-Bicocca,Department of Pediatrics
[6] University Hospital Santa Maria della Misericordia,Department of Translational Sciences, Pediatrics
[7] University Hospital,Department of Pediatrics, Meyer Children’s Hospital, Metabolic and Muscular Unit
[8] University of Bologna,Department of Clinical and Experimental Medicine, Metabolic Diseases, Pediatric Clinic
[9] University Magna Graecia,Department of Pathophysiology and Transplantation, Pediatric Highly Intensive Care Unit
[10] University Federico II,Department of Pediatrics
[11] Division of Metabolism Bambino Gesù Children’s Hospital,undefined
[12] University of Firenze,undefined
[13] University of Catania,undefined
[14] University of Milano,undefined
[15] IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation,undefined
[16] University of Torino,undefined
[17] Rare Diseases Unit,undefined
[18] Pediatric Hospital Istituto Giannina Gaslini,undefined
来源：
Orphanet Journal of Rare Diseases | / 13卷
关键词：
Infantile onset Pompe disease; Alglucosidase alpha; ERT; Recombinant human GAA; rhGAA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 178 条
  • [1] Kishnani PS(2006)Chinese hamster ovary cell-derived recombinant human α-glucosidase in infantile-onset Pompe disease J Pediatr 149 89-97
  • [2] Nicolino M(2007)Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease Neurology 68 99-109
  • [3] Voit T(2009)Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease Pediat Res 66 329-335
  • [4] Rogers RC(2009)Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease Genet Med 11 210-219
  • [5] Tsai AC-H(2010)Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Mol Genet Metab 99 26-33
  • [6] Waterson J(2009)Elimination of antibodies to recombinant enzyme in Pompe’s disease N Engl J Med 360 194-195
  • [7] Kishnani PS(2014)Immune tolerance induced using plasma exchange and rituximab in an infantile Pompe disease patient J Child Neurol 29 850-854
  • [8] Corzo D(2012)Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease Genet Med 14 135-142
  • [9] Nicolino M(2013)B-cell Depletion and Immunomodulation Prior to Initiation of Enzyme Replacement Therapy Blocks the Immune Response to Acid Alpha Glucosidase in Infantile Onset Pompe Disease J Pediatr 163 847-54.e1
  • [10] Byrne B(2015)Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth J Pediatr 166 985-991
12345678910